ReviewAdvanced drug delivery reviews2006
Cardiovascular gene delivery: The good road is awaiting.
Review in Advanced drug delivery reviews, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 55 citations in OpenAlex.
- Article
- A small-diameter vascular graft immobilized peptides for capturing endothelial colony-forming cells.Frontiers in bioengineering and biotechnology · 2023Article
- Oligohistidine and targeting peptide functionalized TAT-NLS for enhancing cellular uptake and promoting angiogenesis in vivo.Journal of nanobiotechnology · 2018Article
- The grafts modified by heparinization and catalytic nitric oxide generation used for vascular implantation in rats.Regenerative biomaterials · 2018Article
- Drug- and Gene-eluting Stents for Preventing Coronary Restenosis.Chonnam medical journal · 2017Review
- Electroporation-mediated delivery of a naked DNA plasmid expressing VEGF to the porcine heart enhances protein expression.Gene therapy · 2010Article
- In vitro and in vivo analysis of expression cassettes designed for vascular gene transfer.Gene therapy · 2008Article
- Construction and characterization of a thrombin-resistant designer FGF-based collagen binding domain angiogen.Biomaterials · 2008Article
- Delivery of large biopharmaceuticals from cardiovascular stents: a review.Biomacromolecules · 2007Review
- Radionuclide reporter gene imaging for cardiac gene therapy.European journal of nuclear medicine and molecular imaging · 2007Review
- Reducible poly(amido ethylenediamine) for hypoxia-inducible VEGF delivery.Journal of controlled release : official journal of the Controlled Release Society · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Atherosclerotic cardiovascular disease is a leading cause of death worldwide. Despite recent improvements in medical, operative, and endovascular treatments, the number of interventions performed annually continues to increase. Unfortunately, the durability of these interventions is limited acutely by thrombotic complications and later by myointimal hyperplasia followed by progression of atherosclerotic disease over time. Despite improving medical management of patients with atherosclerotic disease, these complications appear to be persisting. Cardiovascular gene therapy has the potential to make significant clinical inroads to limit these complications. This article will review the technical aspects of cardiovascular gene therapy; its application for promoting a functional endothelium, smooth muscle cell growth inhibition, therapeutic angiogenesis, tissue engineered vascular conduits, and discuss the current status of various applicable clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.